UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Gastrointestinal perforation due to bevacizumab in colorectal cancer

Annals of surgical oncology, 2007-06, Vol.14 (6), p.1860-1869

2007

Volltextzugriff (PDF)

First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer

Cancer chemotherapy and pharmacology, 2014-02, Vol.73 (2), p.373-380

2014

Volltextzugriff (PDF)

Radiation recall phenomenon secondary to capecitabine : possible role of thymidine phosphorylase

Cancer chemotherapy and pharmacology, 2006-12, Vol.58 (6), p.771-775

2006

Volltextzugriff (PDF)

A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment

Cancer chemotherapy and pharmacology, 2021-09, Vol.88 (3), p.485-497

2021

Volltextzugriff (PDF)

Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2011-12, Vol.68 (6), p.1565-1573

2011

Volltextzugriff (PDF)

Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature

Cancer chemotherapy and pharmacology, 2009-05, Vol.63 (6), p.1017-1022

2009

Volltextzugriff (PDF)

Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer

Cancer chemotherapy and pharmacology, 2008-03, Vol.61 (3), p.349-354

2008

Volltextzugriff (PDF)

Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea

Cancer chemotherapy and pharmacology, 2017-12, Vol.80 (6), p.1055-1062

2017

Volltextzugriff (PDF)

Targeted therapy for oesophageal cancer: an overview

Cancer and metastasis reviews, 2008-06, Vol.27 (2), p.273-288

2008

Volltextzugriff (PDF)

Immunotherapy for pancreatic cancer

Journal of cancer research and clinical oncology, 2016-08, Vol.142 (8), p.1795-1805

2016

Volltextzugriff (PDF)

Dihydropyrimidine dehydrogenase deficiency in an Indian population

Cancer chemotherapy and pharmacology, 2006-09, Vol.58 (3), p.396-401

2006

Volltextzugriff (PDF)

Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency

Cancer chemotherapy and pharmacology, 2016-07, Vol.78 (1), p.151-156

2016

Volltextzugriff (PDF)

Metformin and pancreatic cancer: Is there a role?

Cancer Chemotherapy and Pharmacology, 2016-02, Vol.77 (2), p.235-242

2016

Volltextzugriff (PDF)

A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors

Cancer chemotherapy and pharmacology, 2007-11, Vol.60 (6), p.871-882

2007

Volltextzugriff (PDF)

Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer

Cancer chemotherapy and pharmacology, 2016-10, Vol.78 (4), p.815-824

2016

Volltextzugriff (PDF)

Pharmacology and toxicology of the novel investigational agent Cantrixil (TRX-E-002-1)

Cancer Chemotherapy and Pharmacology, 2017-02, Vol.79 (2), p.303-314

2017

Volltextzugriff (PDF)

Does “OPTINAB” strategy (“stop-and-go”) work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxel–gemcitabine?

Cancer chemotherapy and pharmacology, 2017-08, Vol.80 (2), p.371-375

2017

Volltextzugriff (PDF)

Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma

Cancer chemotherapy and pharmacology, 2016-06, Vol.77 (6), p.1193-1200

2016

Volltextzugriff (PDF)

Nutritional status of patients with locally advanced pancreatic cancer: a pilot study

Supportive care in cancer, 2011-11, Vol.19 (11), p.1729-1734

2011

Volltextzugriff (PDF)

How Shall We Name the Chemotherapy Administration Before and After Metastasectomy? How About “M-Neoadjuvant” and “M-Adjuvant”?

Annals of surgical oncology, 2010-07, Vol.17 (7), p.1970-1970

2010

Volltextzugriff (PDF)

Nutritional status of patients with locally advanced pancreatic cancer

Supportive care in cancer, 2010-10, Vol.19 (11), p.1729-1734

2010

Volltextzugriff (PDF)

Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer

Cancer chemotherapy and pharmacology, 2010, Vol.65 (1), p.107-112

2010

Volltextzugriff (PDF)

Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer

Cancer chemotherapy and pharmacology, 2009-12, Vol.65 (1), p.107-112

2009

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

Nur zeigenMit Volltextzugriff

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)

Publikationsform

Artikel
(23)

Sprache

Englisch
(23)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Zeitschrift / Serie

Menü

Weitere Dienste

Einstellungen

Gastrointestinal perforation due to bevacizumab in colorectal cancer

First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer

Radiation recall phenomenon secondary to capecitabine : possible role of thymidine phosphorylase

A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment

Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors

Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature

Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer

Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea

Targeted therapy for oesophageal cancer: an overview

Immunotherapy for pancreatic cancer

Dihydropyrimidine dehydrogenase deficiency in an Indian population

Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency

Metformin and pancreatic cancer: Is there a role?

A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors

Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer

Pharmacology and toxicology of the novel investigational agent Cantrixil (TRX-E-002-1)

Does “OPTINAB” strategy (“stop-and-go”) work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxel–gemcitabine?

Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma

Nutritional status of patients with locally advanced pancreatic cancer: a pilot study

How Shall We Name the Chemotherapy Administration Before and After Metastasectomy? How About “M-Neoadjuvant” and “M-Adjuvant”?

Nutritional status of patients with locally advanced pancreatic cancer

Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer

Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer

Aktive Filter

Suchergebnisse filtern